No abstract

No abstract

Background-Treatment strategies targeting angiogenesis have revealed promising results in pre-clinical studies and early clinical trials in patients with glioblastomas.Objective-This review evaluates the preclinical and clinical data for cediranib (AZD2171), a potent oral inhibitor of the vascular endothelial growth factor (VEGF) receptor tyrosine kinase.Methods-We summarize both pre-clinical and clinical data for cediranib with a focus on the treatment of glioblastomas.Results/conclusion-Cediranib is an effective drug in patients with glioblastoma acting through inhibition of angiogenesis and normalization of tumor vasculature. Reduction of vasogenic brain edema is a key component of its treatment effect in this patient population. The primary side effects of cediranib include fatigue, diarrhea and hypertension.